Trending Now - Sun Pharma Announces $12 Billion Acquisition of Organon

WHO:

CNBC - Sun Pharmaceutical Industries Ltd. is acquiring Organon & Co.

CNBC - Carrie Cox is the executive chair at Organon.

CNBC - Kirti Ganorkar is the managing director at Sun Pharma.

CNBC - Dilip Shanghvi is the executive chairman of Sun Pharma.

WHAT:

CNBC - Sun Pharma announced it will acquire Organon in an all-cash deal valued at $11.75 billion, including debt.

CNBC - The acquisition price is $14 per share for all outstanding shares of Organon.

Bloomberg Markets - The deal is likely to be one of the biggest outbound deals from India in years.

CNBC - Sun Pharma's revenue is projected to reach $12.4 billion following the acquisition.

CNBC - The innovative medicine segment of Sun Pharma accounted for 20% of total sales in the financial year ending March 2025, which is expected to increase to 27% post-acquisition.

WHERE:

CNBC - Organon is based in New Jersey, USA.

CNBC - Organon has key markets in the U.S., Europe, China, Canada, and Brazil.

WHEN:

CNBC - The acquisition is part of Sun Pharma's strategy for growing its Innovative Medicines business, with no specific date mentioned for the completion of the deal.

WHY:

CNBC - The acquisition is intended to strengthen Sun Pharma's global business and scale its medicine products in the U.S. market.

CNBC - Carrie Cox stated that the transaction offers compelling and immediate value to Organon stockholders.

HOW:

CNBC - The acquisition will be conducted as an all-cash transaction.

(UPDATED April 27, 2026 05:50 UTC)

Sun Pharmaceutical Industries Ltd. has announced its acquisition of Organon & Co. in an all-cash deal valued at $11.75 billion, which includes debt, with the price set at $14 per share for all outstanding shares. This significant move is expected to bolster Sun Pharma's global business and enhance its innovative medicine segment, which is projected to grow from 20% to 27% of total sales following the acquisition. Carrie Cox, the executive chair at Organon, emphasized that this transaction provides compelling and immediate value to Organon stockholders.